Last updated: 2026-11-14 19:25:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Traws Pharma, Inc. (TRAW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.25, with a market capitalization of $4.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.22 to $3.23. This page covers its latest market performance, valuation, price trends and company information.
$4.38M | |
$0.28 | |
$0.31 | |
$0.23 | |
$0.28 | |
530.83K | |
613.34K | |
-- | |
$3.23 | |
$0.22 | |
-- | |
-- |
Traws Pharma, Inc. (TRAW) last closed at $0.25 as of 2026-11-14 00:59:00, down 8.71% ($0.02) from the previous close of $0.28.
During the latest regular trading session, TRAW traded between $0.23 and $0.31, with a volume of 530.83K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Traws Pharma, Inc. (TRAW) moved from $0.22 to $0.25, representing a gain of 15.40% ($0.03).
The stock traded between $0.22 and $0.31 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 284.54 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.2%
TRAW is currently trading at $0.25, placing it 1.2% of the way from its 52-week low of $0.22 to its 52-week high of $3.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Traws Pharma, Inc. and TRAW stock.
Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market cap stands
Traws Pharma reports positive Phase 2a ratutrelvir COVID-19 results and completes key tivoxavir marboxil flu studies ahead of FDA talks.
Ratutrelvir, a once-daily, ritonavir-free oral antiviral therapy in development for COVID-19 infections, showed symptom resolution time comparable to PAXLOVID®, with no viral rebound through Day 28 and fewer
Eligible investors can buy real shares of Traws Pharma, Inc. (TRAW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as Traws Pharma, Inc.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to TRAW, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between TRAW shares and USD.
TRAW Shares to USD
1.00 TRAW shares = 0.254 USD
Calculations are estimates based on the latest available price and are for reference only.
